Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Protein kinase C and Ca(2+) -calmodulin-dependent protein kinase II mediate the enlarged reverse INCX induced by ouabain-increased late sodium current in rabbit ventricular myocytes.

Wu Y, Wang L, Ma J, Song Y, Zhang P, Luo A, Fu C, Cao Z, Wang X, Shryock JC, Belardinelli L.

Exp Physiol. 2015 Apr 1;100(4):399-409. doi: 10.1113/expphysiol.2014.083972. Epub 2015 Mar 10.

2.

Cardiac late Na⁺ current: proarrhythmic effects, roles in long QT syndromes, and pathological relationship to CaMKII and oxidative stress.

Belardinelli L, Giles WR, Rajamani S, Karagueuzian HS, Shryock JC.

Heart Rhythm. 2015 Feb;12(2):440-8. doi: 10.1016/j.hrthm.2014.11.009. Epub 2014 Nov 11. Review.

PMID:
25460862
3.

Intracellular Na+ overload causes oxidation of CaMKII and leads to Ca2+ mishandling in isolated ventricular myocytes.

Viatchenko-Karpinski S, Kornyeyev D, El-Bizri N, Budas G, Fan P, Jiang Z, Yang J, Anderson ME, Shryock JC, Chang CP, Belardinelli L, Yao L.

J Mol Cell Cardiol. 2014 Nov;76:247-56. doi: 10.1016/j.yjmcc.2014.09.009. Epub 2014 Sep 22.

4.

The role of late I Na in development of cardiac arrhythmias.

Antzelevitch C, Nesterenko V, Shryock JC, Rajamani S, Song Y, Belardinelli L.

Handb Exp Pharmacol. 2014;221:137-68. doi: 10.1007/978-3-642-41588-3_7. Review.

5.

Ranolazine attenuates hypoxia- and hydrogen peroxide-induced increases in sodium channel late openings in ventricular myocytes.

Ma J, Song Y, Shryock JC, Hu L, Wang W, Yan X, Zhang P, Belardinelli L.

J Cardiovasc Pharmacol. 2014 Jul;64(1):60-8. doi: 10.1097/FJC.0000000000000090.

PMID:
24705174
6.

Larger late sodium current density as well as greater sensitivities to ATX II and ranolazine in rabbit left atrial than left ventricular myocytes.

Luo A, Ma J, Song Y, Qian C, Wu Y, Zhang P, Wang L, Fu C, Cao Z, Shryock JC.

Am J Physiol Heart Circ Physiol. 2014 Feb;306(3):H455-61. doi: 10.1152/ajpheart.00727.2013. Epub 2013 Dec 6.

7.

Inhibition of the late sodium current slows t-tubule disruption during the progression of hypertensive heart disease in the rat.

Aistrup GL, Gupta DK, Kelly JE, O'Toole MJ, Nahhas A, Chirayil N, Misener S, Beussink L, Singh N, Ng J, Reddy M, Mongkolrattanothai T, El-Bizri N, Rajamani S, Shryock JC, Belardinelli L, Shah SJ, Wasserstrom JA.

Am J Physiol Heart Circ Physiol. 2013 Oct 1;305(7):H1068-79. doi: 10.1152/ajpheart.00401.2013. Epub 2013 Jul 19.

8.

The arrhythmogenic consequences of increasing late INa in the cardiomyocyte.

Shryock JC, Song Y, Rajamani S, Antzelevitch C, Belardinelli L.

Cardiovasc Res. 2013 Sep 1;99(4):600-11. doi: 10.1093/cvr/cvt145. Epub 2013 Jun 10. Review.

9.

A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias.

Belardinelli L, Liu G, Smith-Maxwell C, Wang WQ, El-Bizri N, Hirakawa R, Karpinski S, Li CH, Hu L, Li XJ, Crumb W, Wu L, Koltun D, Zablocki J, Yao L, Dhalla AK, Rajamani S, Shryock JC.

J Pharmacol Exp Ther. 2013 Jan;344(1):23-32. doi: 10.1124/jpet.112.198887. Epub 2012 Sep 25.

PMID:
23010360
10.

An apoptosis signal-regulating kinase 1 inhibitor reduces cardiomyocyte apoptosis and infarct size in a rat ischemia-reperfusion model.

Gerczuk PZ, Breckenridge DG, Liles JT, Budas GR, Shryock JC, Belardinelli L, Kloner RA, Dai W.

J Cardiovasc Pharmacol. 2012 Sep;60(3):276-82. doi: 10.1097/FJC.0b013e31825ea0fa.

PMID:
22635076
11.

Block of Na+ currents and suppression of action potentials in embryonic rat dorsal root ganglion neurons by ranolazine.

Hirakawa R, El-Bizri N, Shryock JC, Belardinelli L, Rajamani S.

Neuropharmacology. 2012 Jun;62(7):2251-60. doi: 10.1016/j.neuropharm.2012.01.021. Epub 2012 Feb 2.

PMID:
22313527
12.

Calmodulin kinase II and protein kinase C mediate the effect of increased intracellular calcium to augment late sodium current in rabbit ventricular myocytes.

Ma J, Luo A, Wu L, Wan W, Zhang P, Ren Z, Zhang S, Qian C, Shryock JC, Belardinelli L.

Am J Physiol Cell Physiol. 2012 Apr 15;302(8):C1141-51. doi: 10.1152/ajpcell.00374.2011. Epub 2011 Dec 21.

13.

Structure-activity relationships of 2-amino-3-aroyl-4-[(4-arylpiperazin-1-yl)methyl]thiophenes. Part 2: Probing the influence of diverse substituents at the phenyl of the arylpiperazine moiety on allosteric enhancer activity at the A₁ adenosine receptor.

Romagnoli R, Baraldi PG, Carrion MD, Cara CL, Cruz-Lopez O, Salvador MK, Preti D, Tabrizi MA, Shryock JC, Moorman AR, Vincenzi F, Varani K, Borea PA.

Bioorg Med Chem. 2012 Jan 15;20(2):996-1007. doi: 10.1016/j.bmc.2011.11.044. Epub 2011 Dec 1.

PMID:
22182575
14.

Selective action of metoprolol to attenuate regadenoson-induced tachycardia in conscious dogs.

Zhao G, Zhang S, Shryock JC, Xu X, Ochoa M, Hintze TH, Belardinelli L.

J Nucl Cardiol. 2012 Feb;19(1):109-17. doi: 10.1007/s12350-011-9481-x. Epub 2011 Dec 2.

PMID:
22135160
15.

Nav1.5-dependent persistent Na+ influx activates CaMKII in rat ventricular myocytes and N1325S mice.

Yao L, Fan P, Jiang Z, Viatchenko-Karpinski S, Wu Y, Kornyeyev D, Hirakawa R, Budas GR, Rajamani S, Shryock JC, Belardinelli L.

Am J Physiol Cell Physiol. 2011 Sep;301(3):C577-86. doi: 10.1152/ajpcell.00125.2011. Epub 2011 Jun 15.

16.

Antiadrenergic and hemodynamic effects of ranolazine in conscious dogs.

Zhao G, Walsh E, Shryock JC, Messina E, Wu Y, Zeng D, Xu X, Ochoa M, Baker SP, Hintze TH, Belardinelli L.

J Cardiovasc Pharmacol. 2011 Jun;57(6):639-47. doi: 10.1097/FJC.0b013e31821458e8.

17.

Late sodium current contributes to the reverse rate-dependent effect of IKr inhibition on ventricular repolarization.

Wu L, Ma J, Li H, Wang C, Grandi E, Zhang P, Luo A, Bers DM, Shryock JC, Belardinelli L.

Circulation. 2011 Apr 26;123(16):1713-20. doi: 10.1161/CIRCULATIONAHA.110.000661. Epub 2011 Apr 11.

18.

Reducing the late sodium current improves cardiac function during sodium pump inhibition by ouabain.

Hoyer K, Song Y, Wang D, Phan D, Balschi J, Ingwall JS, Belardinelli L, Shryock JC.

J Pharmacol Exp Ther. 2011 May;337(2):513-23. doi: 10.1124/jpet.110.176776. Epub 2011 Feb 16.

PMID:
21325441
19.

Use-dependent block of cardiac late Na(+) current by ranolazine.

Rajamani S, El-Bizri N, Shryock JC, Makielski JC, Belardinelli L.

Heart Rhythm. 2009 Nov;6(11):1625-31. doi: 10.1016/j.hrthm.2009.07.042. Epub 2009 Jul 28.

20.

Sulfonylureas uncouple glucose-dependence for GPR40-mediated enhancement of insulin secretion from INS-1E cells.

Yang M, Chisholm JW, Soelaiman S, Shryock JC.

Mol Cell Endocrinol. 2010 Feb 5;315(1-2):308-13. doi: 10.1016/j.mce.2009.09.033. Epub 2009 Oct 6.

PMID:
19815053
21.

Ranolazine as a cardioplegia additive improves recovery of diastolic function in isolated rat hearts.

Hwang H, Arcidi JM Jr, Hale SL, Simkhovich BZ, Belardinelli L, Dhalla AK, Shryock JC, Kloner RA.

Circulation. 2009 Sep 15;120(11 Suppl):S16-21. doi: 10.1161/CIRCULATIONAHA.108.844167.

PMID:
19752362
22.

Ranolazine, an antianginal agent, markedly reduces ventricular arrhythmias induced by ischemia and ischemia-reperfusion.

Dhalla AK, Wang WQ, Dow J, Shryock JC, Belardinelli L, Bhandari A, Kloner RA.

Am J Physiol Heart Circ Physiol. 2009 Nov;297(5):H1923-9. doi: 10.1152/ajpheart.00173.2009. Epub 2009 Sep 18.

23.

LQTS mutation N1325S in cardiac sodium channel gene SCN5A causes cardiomyocyte apoptosis, cardiac fibrosis and contractile dysfunction in mice.

Zhang T, Yong SL, Drinko JK, Popović ZB, Shryock JC, Belardinelli L, Wang QK.

Int J Cardiol. 2011 Mar 3;147(2):239-45. doi: 10.1016/j.ijcard.2009.08.047. Epub 2009 Sep 17.

24.

A slowly inactivating sodium current contributes to spontaneous diastolic depolarization of atrial myocytes.

Song Y, Shryock JC, Belardinelli L.

Am J Physiol Heart Circ Physiol. 2009 Oct;297(4):H1254-62. doi: 10.1152/ajpheart.00444.2009. Epub 2009 Aug 21.

25.

Reduction of repolarization reserve unmasks the proarrhythmic role of endogenous late Na(+) current in the heart.

Wu L, Rajamani S, Li H, January CT, Shryock JC, Belardinelli L.

Am J Physiol Heart Circ Physiol. 2009 Sep;297(3):H1048-57. doi: 10.1152/ajpheart.00467.2009. Epub 2009 Jul 10.

26.

The late Na+ current (INa) inhibitor ranolazine attenuates effects of palmitoyl-L-carnitine to increase late INa and cause ventricular diastolic dysfunction.

Wu Y, Song Y, Belardinelli L, Shryock JC.

J Pharmacol Exp Ther. 2009 Aug;330(2):550-7. doi: 10.1124/jpet.109.151936. Epub 2009 Apr 29.

PMID:
19403851
27.

Sinus node dysfunction in ATX-II-induced in-vitro murine model of long QT3 syndrome and rescue effect of ranolazine.

Wu J, Cheng L, Lammers WJ, Wu L, Wang X, Shryock JC, Belardinelli L, Lei M.

Prog Biophys Mol Biol. 2008 Oct-Nov;98(2-3):198-207. doi: 10.1016/j.pbiomolbio.2009.01.003. Epub 2009 Jan 25.

PMID:
19351514
28.

Ranolazine as an adjunct to cardioplegia: a potential new therapeutic application.

Hwang H, Arcidi JM Jr, Hale SL, Simkhovich BZ, Belardinelli L, Dhalla AK, Shryock JC, Kloner RA.

J Cardiovasc Pharmacol Ther. 2009 Jun;14(2):125-33. doi: 10.1177/1074248409333491. Epub 2009 Mar 27.

PMID:
19329672
29.

Contribution of frequency-augmented inward Ca2+ current to myocardial contractility.

Parilak LD, Taylor DG, Song Y, Burkart T, Shryock JC, Curtis AB, Knot HJ.

Can J Physiol Pharmacol. 2009 Jan;87(1):69-75. doi: 10.1139/Y08-087.

PMID:
19142218
30.

Role of late sodium current in modulating the proarrhythmic and antiarrhythmic effects of quinidine.

Wu L, Guo D, Li H, Hackett J, Yan GX, Jiao Z, Antzelevitch C, Shryock JC, Belardinelli L.

Heart Rhythm. 2008 Dec;5(12):1726-34. doi: 10.1016/j.hrthm.2008.09.008. Epub 2008 Sep 6.

31.

Block of tetrodotoxin-sensitive, Na(V)1.7 and tetrodotoxin-resistant, Na(V)1.8, Na+ channels by ranolazine.

Rajamani S, Shryock JC, Belardinelli L.

Channels (Austin). 2008 Nov-Dec;2(6):449-60. Epub 2008 Nov 7.

PMID:
19077543
32.

Synthesis and biological evaluation of 2-amino-3-(4-chlorobenzoyl)-4-[N-(substituted) piperazin-1-yl]thiophenes as potent allosteric enhancers of the A1 adenosine receptor.

Romagnoli R, Baraldi PG, Carrion MD, Cara CL, Cruz-Lopez O, Iaconinoto MA, Preti D, Shryock JC, Moorman AR, Vincenzi F, Varani K, Andrea Borea P.

J Med Chem. 2008 Sep 25;51(18):5875-9. doi: 10.1021/jm800586p. Epub 2008 Aug 26.

PMID:
18729349
33.

Pathophysiology and pharmacology of the cardiac "late sodium current.".

Zaza A, Belardinelli L, Shryock JC.

Pharmacol Ther. 2008 Sep;119(3):326-39. doi: 10.1016/j.pharmthera.2008.06.001. Epub 2008 Jul 1. Review.

PMID:
18662720
34.

Rapid kinetic interactions of ranolazine with HERG K+ current.

Rajamani S, Shryock JC, Belardinelli L.

J Cardiovasc Pharmacol. 2008 Jun;51(6):581-9. doi: 10.1097/FJC.0b013e3181799690.

PMID:
18520952
35.

Late sodium current inhibition as a new cardioprotective approach.

Hale SL, Shryock JC, Belardinelli L, Sweeney M, Kloner RA.

J Mol Cell Cardiol. 2008 Jun;44(6):954-67. doi: 10.1016/j.yjmcc.2008.03.019. Epub 2008 Apr 8. Review.

PMID:
18462746
36.

An increase of late sodium current induces delayed afterdepolarizations and sustained triggered activity in atrial myocytes.

Song Y, Shryock JC, Belardinelli L.

Am J Physiol Heart Circ Physiol. 2008 May;294(5):H2031-9. doi: 10.1152/ajpheart.01357.2007. Epub 2008 Feb 29.

37.

Inhibition of late sodium current to reduce electrical and mechanical dysfunction of ischaemic myocardium.

Shryock JC, Belardinelli L.

Br J Pharmacol. 2008 Mar;153(6):1128-32. Epub 2007 Dec 10.

38.

Augmentation of late sodium current unmasks the proarrhythmic effects of amiodarone.

Wu L, Rajamani S, Shryock JC, Li H, Ruskin J, Antzelevitch C, Belardinelli L.

Cardiovasc Res. 2008 Feb 1;77(3):481-8. Epub 2007 Nov 13.

39.

Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans.

Lieu HD, Shryock JC, von Mering GO, Gordi T, Blackburn B, Olmsted AW, Belardinelli L, Kerensky RA.

J Nucl Cardiol. 2007 Jul;14(4):514-20.

PMID:
17679059
40.

Characterization of the potency, selectivity, and pharmacokinetic profile for six adenosine A2A receptor antagonists.

Yang M, Soohoo D, Soelaiman S, Kalla R, Zablocki J, Chu N, Leung K, Yao L, Diamond I, Belardinelli L, Shryock JC.

Naunyn Schmiedebergs Arch Pharmacol. 2007 Apr;375(2):133-44. Epub 2007 Feb 20.

PMID:
17310264
41.

Antilipolytic activity of a novel partial A1 adenosine receptor agonist devoid of cardiovascular effects: comparison with nicotinic acid.

Dhalla AK, Santikul M, Smith M, Wong MY, Shryock JC, Belardinelli L.

J Pharmacol Exp Ther. 2007 Apr;321(1):327-33. Epub 2007 Jan 4.

PMID:
17204748
43.

Blocking late sodium current reduces hydrogen peroxide-induced arrhythmogenic activity and contractile dysfunction.

Song Y, Shryock JC, Wagner S, Maier LS, Belardinelli L.

J Pharmacol Exp Ther. 2006 Jul;318(1):214-22. Epub 2006 Mar 24.

PMID:
16565163
44.

A novel partial agonist of the A(1)-adenosine receptor and evidence of receptor homogeneity in adipocytes.

Fatholahi M, Xiang Y, Wu Y, Li Y, Wu L, Dhalla AK, Belardinelli L, Shryock JC.

J Pharmacol Exp Ther. 2006 May;317(2):676-84. Epub 2006 Jan 12.

PMID:
16410404
45.

Use of preclinical assays to predict risk of drug-induced torsades de pointes.

Belardinelli L, Shryock JC, Wu L, Song Y.

Heart Rhythm. 2005 Nov;2(2 Suppl):S16-22. Review.

PMID:
16253927
46.

An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts.

Wu L, Shryock JC, Song Y, Belardinelli L.

J Pharmacol Exp Ther. 2006 Feb;316(2):718-26. Epub 2005 Oct 18.

PMID:
16234410
47.

A mechanistic approach to assess the proarrhythmic risk of QT-prolonging drugs in preclinical pharmacologic studies.

Shryock JC, Song Y, Wu L, Fraser H, Belardinelli L.

J Electrocardiol. 2004;37 Suppl:34-9. Review.

PMID:
15534790
48.

Synthesis of 2-amino-3-heteroaroylthiophenes and evaluation of their activity as potential allosteric enhancers at the human A1 receptor.

Baraldi PG, Pavani MG, Shryock JC, Moorman AR, Iannotta V, Borea PA, Romagnoli R.

Eur J Med Chem. 2004 Oct;39(10):855-65.

PMID:
15464619
49.

Antagonism by ranolazine of the pro-arrhythmic effects of increasing late INa in guinea pig ventricular myocytes.

Song Y, Shryock JC, Wu L, Belardinelli L.

J Cardiovasc Pharmacol. 2004 Aug;44(2):192-9.

PMID:
15243300
50.

Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome.

Wu L, Shryock JC, Song Y, Li Y, Antzelevitch C, Belardinelli L.

J Pharmacol Exp Ther. 2004 Aug;310(2):599-605. Epub 2004 Mar 18.

PMID:
15031300

Supplemental Content

Loading ...
Support Center